Downregulation of microRNA‑605 indicates poor prognosis and promotes the progression of osteosarcoma
Affiliations: Department of Spinal Surgery, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
- Published online on: October 19, 2020 https://doi.org/10.3892/ol.2020.12233
Copyright: © Yi
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Osteosarcoma (OS) is a type of primary bone tumor, which is one of the leading causes of cancer‑related death. MicroRNA (miR)‑605 has been demonstrated to act as a prognostic biomarker and therapeutic target in various cancers, such as breast cancer and non‑small cell lung cancer, but its function in OS remains unclear. The aim of the present study was to investigate the prognostic value of miR‑605 in patients with OS by evaluating its expression levels and to explore the biological function of miR‑605 in OS progression. For this purpose, tumor tissues and adjacent normal tissues were collected from OS patients, and the expression of miR‑605 in the collected tissues and OS MG63, U2OS, HOS, and SAOS‑2 cell lines was detected by quantitative real‑time PCR. The prognostic value of miR‑605 was evaluated by Kaplan‑Meier survival curves and Cox regression analysis. The effects of miR‑605 on OS cell proliferation, migration and invasion were analyzed by the CCK‑8 and transwell assays, respectively. The results of the present study revealed that miR‑605 was significantly downregulated in OS tissues compared with adjacent normal tissues, which was associated with the clinical stage and distant metastasis of patients. Additionally, the downregulation of miR‑605 predicted the poor prognosis of patients with OS and served as an independent prognostic indicator. The downregulation of miR‑605 enhanced cell proliferation, migration, and invasion of OS cells, which suggested that miR‑605 may be involved in the progression of OS. The findings of the present study provide a new therapeutic target for the treatment of patients with OS.